Researchers have engineered a vaccine using virus-like particles that target Tau tangles in mouse models of Alzheimer's disease. Following the administration of the vaccine, the mice developed antibodies that cleared tau proteins, with the response lasting for a month. The mice also showed improvements in memory based tests and had less brain shrinkage than their peers who did not receive the vaccine. This suggests the vaccine prevented apoptosis. Researchers hope to move the vaccine to human clinical trials in the future.
Researchers report they have found no increased risk of autoimmune diseases in girls who received the HPV4 vaccine. The study adds to a growing body of evidence for the safety of the vaccine.
Head and neck cancers involving HPV are on the rise and researchers fear we may be seeing the start of an epidemic.